Depo-Provera MDL 3140 Update: Settlement Reached, But September Rule 702 Hearing Still Looms

The Depo-Provera MDL has entered a materially different phase. The Northern District of Florida’s official MDL orders page identifies Case Management Order No. 12, entered July 28, 2026, as the court’s latest order addressing the settlement, data administration, and ongoing state-court litigation. The same court page lists Pretrial Order No. 30A, entered June 23, 2026, concerning the application of preemption and Rule 702 rulings to individual actions.¹⁸ 

According to the July 28 order described in the litigation record, the parties signed a Master Settlement Agreement on July 21, 2026. The settlement framework is intended to provide a resolution path for eligible plaintiffs in the federal MDL, but the publicly available record does not disclose individual compensation amounts or the complete eligibility and valuation rules. The distinction matters as an executed settlement agreement is not the same thing as a publicly disclosed schedule of payments or a judicial finding on liability. 

The court’s July 28 order also moved the litigation away from the original pilot-case track for matters covered by the settlement framework. The first bellwether case, Toney v. Pfizer, had previously been scheduled for trial on December 7, 2026; that trial setting has been vacated. The court’s current public calendar instead lists a September 18, 2026 Rule 702 motions hearing following the case-management conference.¹⁹ 

The settlement should therefore be viewed as a major procedural development, not as a final resolution of the entire Depo-Provera litigation. The federal MDL still contains cases that may fall outside the settlement framework, while related state-court proceedings continue separately. 

What “Is” and “Is Not” Public About the Settlement 

One of the easiest mistakes in reporting this development is to treat estimates or settlement commentary as if they were final settlement terms. The July 28 CMO is the proper starting point for the current status. The court’s public orders page confirms the existence and subject matter of CMO No. 12, but the settlement’s detailed compensation mechanics remain confidential.²⁰ 

The parties signed a Master Settlement Agreement on July 21, 2026, establishing a settlement framework for plaintiffs who meet specified eligibility requirements. BrownGreer is involved in the litigation’s data-administration infrastructure, although its precise role should be described as administrative or proposed unless confirmed by the operative order. The prior Toney bellwether trial setting has been vacated, and the pilot-case schedule has been modified in light of the settlement, while state-court and non-settling federal cases remain part of the broader litigation. Without access to the confidential settlement documents, details such as eligibility percentages, payment tiers, award ranges, valuation formulas, documentary requirements, registration deadlines, and filing cutoffs should not be presented as established facts; references to a specific percentage of plaintiffs being excluded should instead be characterized as estimates. 

The Numbers Behind the MDL 

The federal docket has continued to grow rapidly. The JPML’s June 1, 2026 report listed 5,508 pending actions in MDL 3140. Its July 1, 2026 report listed 5,830 pending actions, an increase of 322 in one month. The July report also recorded 5,916 total historical actions in the MDL.²¹ 

Those numbers are useful for showing the scale of the litigation, but they should not be used to imply that every pending action will participate in the settlement. A docket count measures filed federal actions at a particular point in time. It does not establish settlement eligibility, causation, liability, or claim value. 

The original draft also described the late-July docket as approximately 6,289 actions. 

The Cases Outside the Settlement 

The settlement does not resolve the underlying legal and scientific issues in cases outside its framework. Those matters will continue to involve questions of general causation, federal preemption of state-law failure-to-warn claims, the admissibility of expert testimony under Federal Rule of Evidence 702, and whether individual plaintiffs can establish product use, exposure, injury, and other applicable state-law elements. Rather than characterizing the remaining cases as necessarily the “harder” claims, it is more accurate to state that they remain subject to the substantive and evidentiary issues that the settlement does not adjudicate. 

Why September 18 Still Matters 

The Northern District of Florida’s official MDL page currently lists September 18, 2026 at 9:00 a.m. Central Time as a case-management conference, followed by a Rule 702 motions hearing.²² The hearing is therefore still an important event for the federal cases that remain subject to the court’s expert-admissibility process. 

A Rule 702 ruling can significantly affect general-causation evidence, but it would not automatically establish liability, resolve individual cases, or bind separate state-court proceedings. Its influence will depend on the issues decided and how other courts treat the federal MDL ruling. Rather than stating that exclusion of plaintiffs’ experts would necessarily lead to dismissal of every non-settling case, it is more accurate to say that excluding critical general-causation testimony could create a substantial obstacle for plaintiffs who rely on that evidence to establish causation. 

The Scientific Background 

The scientific dispute is an important part of the litigation’s context, but the article should distinguish an epidemiological association from a judicial finding of causation. 

A major study cited in the litigation was published in The BMJ in March 2024. Roland et al., “Use of progestogens and the risk of intracranial meningioma: national case-control study,” BMJ 2024;384:e078078, examined data from the French National Health Data System. The study included 18,061 women who had undergone intracranial surgery for meningioma and 90,305 matched controls. For injectable medroxyprogesterone acetate at 150 mg, prolonged use was associated with an increased risk of surgically treated intracranial meningioma. The study itself described the finding as an association and called for further research; it did not purport to establish legal causation in individual cases.²³ 

The study is important evidence in the scientific debate, but it should not be described as proving that Depo-Provera causes meningioma. That distinction becomes particularly important when discussing Rule 702 and general causation. 

The FDA Label Change 

The U.S. prescribing information for Depo-Provera CI was revised in December 2025 to add meningioma to the Warnings and Precautions section. The FDA-hosted label identifies “Warnings and Precautions, Meningioma (5.4)” as a December 2025 change. The label states that cases of meningioma have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use, and directs clinicians to monitor for signs and symptoms and discontinue Depo-Provera CI if a meningioma is diagnosed.²⁴ 

That regulatory change is a significant fact in the litigation because it changed the U.S. product labeling. It should not, however, be characterized as an FDA finding of tort liability or as a regulatory determination that the drug legally caused the tumors alleged in the MDL. The label change is evidence in the regulatory record; questions of causation, adequacy of earlier warnings, preemption, and liability remain legal issues for the courts. 

Preemption and the Federal Court’s Rulings 

Federal preemption remains a central issue in the litigation. The Northern District of Florida’s orders page identifies Pretrial Order No. 30, entered January 27, 2026, and Pretrial Order No. 30A, entered June 23, 2026, as orders addressing how rulings on preemption and Rule 702 motions apply to individual actions.²⁵ 

The important point for readers is procedural. The court structured these common issues so that rulings can have consequences beyond the five pilot cases. That does not mean the court has already ruled for either side on the merits of the preemption dispute. The original article correctly identified preemption as unresolved, and that caution should be retained. 

Without a final ruling, it is more accurate to say that the preemption issue remained under consideration and was being addressed through the court’s coordinated briefing and pretrial orders. 

State-Court Litigation 

The federal MDL is only one part of the broader Depo-Provera litigation. The Northern District of Florida’s CMO materials have repeatedly addressed coordination with state proceedings, and the July 28, 2026 CMO is specifically described by the court as addressing ongoing state-court litigation.²⁶ 

A federal MDL settlement does not, by itself, dispose of separate state-court cases. The practical consequence is that firms with both federal and state inventories need to maintain separate tracking for settlement status, governing law, court deadlines, and any state-specific evidentiary or procedural developments. 

Why a Settlement Can Happen Before a Verdict 

A mass-tort settlement does not require a prior jury verdict. MDL proceedings facilitate coordinated discovery, motion practice, expert proceedings, and bellwether preparation, but parties may negotiate a resolution when the risks, costs, and uncertainties of continued litigation become significant. The Depo-Provera settlement is notable because it emerged before a bellwether verdict and while important scientific and legal issues remained unresolved. However, the settlement does not establish the validity of plaintiffs’ theories or Pfizer’s liability; rather, it reflects a negotiated resolution for a defined group of claims. For mass-tort practitioners, the key lesson is procedural: settlement negotiations can supersede a bellwether schedule even when major merits and evidentiary defenses remain unresolved. 

What to Watch Through the Rest of 2026 

• September 18, 2026 – The court’s current calendar lists a Rule 702 motions hearing following the case-management conference. Its effect on non-settling federal cases will depend on the court’s rulings and the claims remaining outside the settlement framework.²⁷

• Settlement administration – The next important practical development is publication or communication of the operative eligibility, documentation, registration, and valuation procedures. Until those terms are released, counsel should avoid relying on unofficial payout figures or eligibility lists.

• Settlement administrator / data administration – BrownGreer has long been part of the MDL’s data-administration structure, and CMO No. 12 addresses settlement-related administration. Counsel should distinguish an administrative role from any final appointment or authority under the operative settlement documents.²⁸

• State-court proceedings – Separate state cases will continue to require their own docket and deadline tracking. A federal MDL settlement does not automatically resolve those matters.

• Non-settling federal cases – These cases may become the principal focus of the court’s remaining preemption, Rule 702, and case-specific proceedings.

Ultimately, MDL 3140 has moved from an expanding pretrial litigation toward settlement administration for a defined group of federal plaintiffs, but the settlement does not make the underlying litigation disappear. The verified federal docket stood at 5,830 pending actions as of July 1, 2026, and the Northern District of Florida continues to list a September 18 Rule 702 hearing.²⁹ 

The most important editorial correction is one of framing. The settlement is not a verdict, the FDA label change is not a judicial finding of causation, an epidemiological association is not the same as legal causation, and a federal MDL ruling does not automatically resolve separate state-court cases.  

For firms handling Depo-Provera inventories, the immediate priority is straightforward, like separate clients who may participate in the federal settlement from those who will continue litigating, preserve the records needed to establish product use and injury, and track the court’s Rule 702 and preemption developments without assuming that any one of those events determines every individual claim.